Roche Holding AG (RHHBY) shares climbed 1.18% to $59.81, a gain of $0.70, after the Swiss pharmaceutical group reported strong third-quarter sales and a series of major US regulatory approvals. Quarterly sales grew 7% at constant exchange rates, while demand for key medicines and steady progress across the drug pipeline underpinned the company's performance.

Pharmaceutical Sales Growth

Roche generated CHF 46.5 billion in group sales during the first nine months of 2026, an increase of 6% at constant exchange rates — a reporting measure that strips out currency swings and is widely used across the pharmaceutical industry to show underlying demand. The stronger Swiss franc held reported growth to 1%, despite continued demand for medicines and diagnostic products. Third-quarter revenue rose 8% in Swiss francs as currency pressure eased during the period.

The Pharmaceuticals Division posted CHF 36.2 billion in sales, up 7% at constant exchange rates. The company's five leading medicines — Xolair, Hemlibra, Ocrevus, Phesgo, and Vabysmo — generated combined revenue of CHF 16.8 billion, delivering 12% constant-currency growth and supporting performance across several major disease categories.

Regional figures showed differing demand across Roche's markets. Japan recorded 25% constant-currency growth, international markets expanded 10%, and the United States grew 5%. Older medicines, however, faced biosimilar competition — rival versions of biologic drugs that typically enter the market once regulatory exclusivity ends — which reduced sales of several established treatments, a dynamic reshaping revenue across the industry as major therapies lose exclusivity.

FDA Approvals Expand Roche's Pipeline

Roche secured multiple US approvals during the quarter, broadening treatment options in cancer and autoimmune disease. The FDA approved Tecentriq in combination with chemotherapy for certain patients with stage III colon cancer following surgery; clinical trial results showed the combination cut the risk of disease recurrence or death by 50% compared with chemotherapy alone.

The agency also approved Enspryng for thyroid eye disease, giving eligible patients an at-home treatment option. In addition, Roche received Priority Review for fenebrutinib in both relapsing and primary progressive multiple sclerosis — a designation the FDA reserves for therapies that may offer substantial improvements over existing options and that shortens the review timeline — leaving a regulatory decision on the multiple sclerosis candidate among the next milestones to watch. Phase III trials showed the drug reduced relapse rates by 51% and 58% against teriflunomide.

Beyond regulatory milestones, Roche reported positive clinical results across kidney disease, cancer, diabetes, and obesity programs. Its experimental diabetes treatment, enicepatide, achieved average weight loss of 15.5% at the highest dose after 48 weeks. The company continues to broaden its development pipeline and targets up to 20 new medicines by 2030.

Diagnostics Gains and 2026 Outlook

The Diagnostics Division generated CHF 10.3 billion in nine-month sales, up 4% at constant exchange rates. Strong demand for laboratory and pathology products helped offset pricing reforms affecting diagnostic sales in China. North America 9% growth, while Latin America expanded 12% at constant exchange rates.

The FDA also cleared Roche's Elecsys pTau217 blood test to support Alzheimer's disease assessment. The test enables clinicians to identify amyloid pathology through a single biomarker in both primary and specialist care settings, and Roche plans to use its existing US laboratory equipment network to support wider access.

Roche maintained its full-year 2026 outlook following the third-quarter performance and regulatory progress. The company expects mid-single-digit group sales growth and high-single-digit core earnings-per-share growth at constant exchange rates. It also anticipates another dividend increase in Swiss francs while expanding manufacturing and research operations in the United States. With the fenebrutinib review still pending and additional pipeline programs in testing across kidney disease, cancer, diabetes, and obesity, the coming quarters offer clear regulatory and clinical markers against which the company's stated targets can be tracked.